Scribe Therapeutics filed for a Nasdaq initial public offering, testing investor appetite for early-stage gene-editing companies. The filing positions Scribe as a CRISPR enzyme developer created roughly nine years ago. The IPO move comes as public markets look for durable pipelines and clearer path-to-clinic timelines in gene editing, where platform validation and delivery strategies often determine long-term valuation. If approved and executed, the offering would provide new capital for clinical execution and platform scaling, while also drawing additional attention to the company’s CRISPR approach at a time of heightened competition among gene-editing startups.